

InspireMD, Inc.  
Form 8-K  
May 20, 2013

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): May 16, 2013

**InspireMD, Inc.**

(Exact name of registrant as specified in its charter)

|   |                          |                                      |
|---|--------------------------|--------------------------------------|
| Delaware  | 001-35731                | 26-2123838                           |
| (State or other jurisdiction<br>of incorporation) | (Commission File Number) | (IRS Employer<br>Identification No.) |

4 Menorat Hamaor St.

67448

Tel Aviv, Israel  
(Address of principal executive offices) (Zip Code)

Edgar Filing: InspireMD, Inc. - Form 8-K

Registrant's telephone number, including area code: 972-3-691-7691

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4 (c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 8.01 Other Events.**

On May 16, 2013, InspireMD, Inc. (the “Company”) issued a press release announcing that it will present six-month results from the MASTER (MGuard for Acute ST Elevation Reperfusion) trial of its MGuard™ Embolic Protection Stent. The results will be presented on May 23, 2013 at EuroPCR, the official annual meeting of the European Association for Percutaneous Cardiovascular Interventions, at the Palais Des Congrès in Paris. The results will also be presented through a conference call and webcast on the same date.

A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.

**Item 9.01 Financial Statements and Exhibits.**

(d)Exhibits

| <b>Exhibit Number</b> | <b>Description</b>               |
|-----------------------|----------------------------------|
| 99.1                  | Press Release dated May 16, 2013 |

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**InspireMD, Inc.**

Date: May 20, 2013 By: /s/ Craig Shore

Name: Craig Shore

Title: Chief Financial Officer

**EXHIBIT INDEX**

| <b>Exhibit Number</b> | <b>Description</b>               |
|-----------------------|----------------------------------|
| 99.1                  | Press Release dated May 16, 2013 |